EGRX - U.S. Court postpones vasopressin trial between Eagle and Endo Par Innovation to February 1

Eagle Pharmaceuticals (EGRX) announces that the United States District Court postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern.The trial is now scheduled to begin remotely starting February 1, 2021 and is expected to be concluded by February 5, 2021. EGRX is -1.2% to $49.11Source: Press Release

For further details see:

U.S. Court postpones vasopressin trial between Eagle and Endo Par Innovation to February 1